WealthOne’s AbbVie ABBV Stock Holding History

WealthOne’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-454	Closed	-$41K	–	79
2018 Q4	$41K	Buy	+454	New	+$39.9K	0.04%	191

Other funds holding ABBV

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

OAG

Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

WealthOne's ABBV Position: Q1 2019 in Review

WealthOne sold out of AbbVie (ABBV) in Q1 2019, closing a stake of 454 shares — an estimated $41K sold.

WealthOne first reported a position in ABBV in Q4 2018 and held it in 1 quarter. The position peaked at $41K in Q4 2018. 2,034 funds tracked by Wall St. Rank hold ABBV as of Q1 2019.

WealthOne reported no remaining AbbVie position as of Q1 2019 after selling out during the quarter.
WealthOne sold 454 AbbVie shares in Q1 2019, an estimated $41K.
WealthOne first reported a position in AbbVie in Q4 2018 and held it in 1 quarter.
WealthOne's AbbVie position peaked at $41K in Q4 2018.
2,034 funds tracked by Wall St. Rank held AbbVie as of Q1 2019.

Based on WealthOne's 13F filing for Q1 2019, filed 16 May 2019.